Ventricular Tachycardia in Ischemic Cardiomyopathy; a Combined Endo-Epicardial Ablation Within the First Procedure Versus a Stepwise Approach (EPILOGUE)
Primary Purpose
Ventricular Tachycardia, Ischemic Cardiomyopathy
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
combined endo/epicardial approach
stepwise approach
Sponsored by
About this trial
This is an interventional treatment trial for Ventricular Tachycardia focused on measuring epicardial catheter ablation
Eligibility Criteria
Inclusion Criteria:
- clinical indication for ablation of a monomorphic ventricular tachycardia referred to one of the participating ablation centers
- history of ischemic heart disease
- ICD carrier or ICD implantation planned after the ablation
- informed written consent
Exclusion Criteria:
- current unstable angina as defined by current european guidelines
- AMI < 30 days or in case of incessant VT < 14 days
- absence of visualisation of the coronary anatomy (coronary angiogram /CT-angiogram)
- significant coronary stenosis approachable and clinically relevant for intervention
- presence of a mobile left ventricle thrombus seen on (contrast) echocardiography or MRI
- previous pericarditis
- presence of mitral/aortic mechanical valves prosthesis; previous coronary artery bypass graft; any other thoracic surgery that could cause pericardial adhesions
- previous thoracic radiation therapy
- contra-indication for general anaesthesia
- age below 18 years
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
combined endo/epicardial approach
stepwise approach
Arm Description
combining endocardial scar homogenization with epicardial scar homogenization in the first VT ablation approach
endocardial scar homogenization only at the first VT ablation procedure
Outcomes
Primary Outcome Measures
Recurrence (Recurrence of any ventricular tachycardia)
Recurrence of any ventricular tachycardia: any appropriate ICD therapy or VT > 30 seconds of duration recorded by ICD interrogations or on clinical event recorded by electrocardiogram with an initial blanking period of 1 week after the ablation procedure
Secondary Outcome Measures
procedure success
success: non-inducibility of any sustained monomorphic VT partial success: non-inducibility of clinical VT (inducibility of non-clinical VT excluding polymorphic VT, VT with cycle length < 200ms)
procedure related (serious) adverse events
major: death, acute myocardial infarction (AMI) / coronary artery damage, major bleeding - type III and V, abdominal bleeding, tamponade > 80cm3, late tamponade, ischemic cerebral event minor: dry right ventricle puncture, drainable hemopericardium, postprocedural precordial pain, phrenic nerve injury, minor bleeding - type II
procedure time, fluoroscopy and radiofrequency time
time to recurrence to ventricular arrhythmia
number of appropriate ICD therapy on follow-up
number of ventricular arrhythmia related hospitalizations
free of antiarrhythmic drugs on follow-up
repeat procedure
incessant VT or VT storm on follow-up
mortality
Full Information
NCT ID
NCT02358746
First Posted
January 27, 2015
Last Updated
February 6, 2015
Sponsor
Erasmus Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT02358746
Brief Title
Ventricular Tachycardia in Ischemic Cardiomyopathy; a Combined Endo-Epicardial Ablation Within the First Procedure Versus a Stepwise Approach
Acronym
EPILOGUE
Official Title
Ventricular Tachycardia in Ischemic Cardiomyopathy; a Combined Endo-Epicardial Ablation Within the First Procedure Versus a Stepwise Approach a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
February 2015
Overall Recruitment Status
Unknown status
Study Start Date
May 2015 (undefined)
Primary Completion Date
May 2019 (Anticipated)
Study Completion Date
December 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Erasmus Medical Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Rationale: Nowadays ventricular tachycardia (VT) ablation in structural heart disease is performed primarily by early referral; while at the same time we still struggle with the limited longterm ablation success of endocardial VT ablation. An underestimated number of VTs from ischemic substrate have an epicardial exit. However, one cannot accurately predict who is in need of epicardial ablation. The investigators hypothesise endo/epicardial substrate homogenization in a first approach to be superior to endocardial substrate homogenization alone, in terms of recurrence on follow-up.
Objective: To show superiority of a combined endo/epicardial approach compared to a stepwise approach in the ablation of ventricular tachycardia in a population with ischemic cardiomyopathy on VT recurrence.
Study design: Multicenter prospective open randomized controlled trial. Study population: All patients above 18 years with an ischemic cardiomyopathy being referred for a ventricular tachycardia ablation.
Intervention: One group undergoes endo/epicardial ablation and the other group has endocardial ablation only as a first approach.
Main study parameters/endpoints: The main study endpoint is the difference in recurrences of ventricular tachycardia on follow-up - clinical or on implantable cardioverter defibrillator (ICD) interrogation - between the two ablation groups; secondary endpoints are procedure success and safety.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ventricular Tachycardia, Ischemic Cardiomyopathy
Keywords
epicardial catheter ablation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
125 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
combined endo/epicardial approach
Arm Type
Experimental
Arm Description
combining endocardial scar homogenization with epicardial scar homogenization in the first VT ablation approach
Arm Title
stepwise approach
Arm Type
Active Comparator
Arm Description
endocardial scar homogenization only at the first VT ablation procedure
Intervention Type
Other
Intervention Name(s)
combined endo/epicardial approach
Other Intervention Name(s)
endo /epicardial catheter ablation
Intervention Type
Other
Intervention Name(s)
stepwise approach
Intervention Description
endocardial scar homogenization only at the first VT ablation procedure
Primary Outcome Measure Information:
Title
Recurrence (Recurrence of any ventricular tachycardia)
Description
Recurrence of any ventricular tachycardia: any appropriate ICD therapy or VT > 30 seconds of duration recorded by ICD interrogations or on clinical event recorded by electrocardiogram with an initial blanking period of 1 week after the ablation procedure
Time Frame
2 years
Secondary Outcome Measure Information:
Title
procedure success
Description
success: non-inducibility of any sustained monomorphic VT partial success: non-inducibility of clinical VT (inducibility of non-clinical VT excluding polymorphic VT, VT with cycle length < 200ms)
Time Frame
2 years
Title
procedure related (serious) adverse events
Description
major: death, acute myocardial infarction (AMI) / coronary artery damage, major bleeding - type III and V, abdominal bleeding, tamponade > 80cm3, late tamponade, ischemic cerebral event minor: dry right ventricle puncture, drainable hemopericardium, postprocedural precordial pain, phrenic nerve injury, minor bleeding - type II
Time Frame
30 days
Title
procedure time, fluoroscopy and radiofrequency time
Time Frame
one day
Title
time to recurrence to ventricular arrhythmia
Time Frame
2 years
Title
number of appropriate ICD therapy on follow-up
Time Frame
2 years
Title
number of ventricular arrhythmia related hospitalizations
Time Frame
2 years
Title
free of antiarrhythmic drugs on follow-up
Time Frame
2 years
Title
repeat procedure
Time Frame
2 years
Title
incessant VT or VT storm on follow-up
Time Frame
2 years
Title
mortality
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
clinical indication for ablation of a monomorphic ventricular tachycardia referred to one of the participating ablation centers
history of ischemic heart disease
ICD carrier or ICD implantation planned after the ablation
informed written consent
Exclusion Criteria:
current unstable angina as defined by current european guidelines
AMI < 30 days or in case of incessant VT < 14 days
absence of visualisation of the coronary anatomy (coronary angiogram /CT-angiogram)
significant coronary stenosis approachable and clinically relevant for intervention
presence of a mobile left ventricle thrombus seen on (contrast) echocardiography or MRI
previous pericarditis
presence of mitral/aortic mechanical valves prosthesis; previous coronary artery bypass graft; any other thoracic surgery that could cause pericardial adhesions
previous thoracic radiation therapy
contra-indication for general anaesthesia
age below 18 years
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Astrid Hendriks, MD
Phone
0031107032710
Email
a.a.hendriks@erasmusmc.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Tamas Szilil-Torok, MD, PhD
Phone
031107035018
Email
t.szilitorok@erasmusmc.nl
12. IPD Sharing Statement
Learn more about this trial
Ventricular Tachycardia in Ischemic Cardiomyopathy; a Combined Endo-Epicardial Ablation Within the First Procedure Versus a Stepwise Approach
We'll reach out to this number within 24 hrs